Loss of STK11 expression is an early event in prostate carcinogenesis and predicts therapeutic response to targeted therapy against MAPK/p38

Prostate cancer (PCa) is the second leading cause of cancer-related death in men; however, the molecular mechanisms leading to its development and progression are not yet fully elucidated. Of note, it has been recently shown that conditional stk11 knockout mice develop atypical hyperplasia and prost...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Autophagy 2015-11, Vol.11 (11), p.2102-2113
Hauptverfasser: Grossi, Valentina, Lucarelli, Giuseppe, Forte, Giovanna, Peserico, Alessia, Matrone, Antonio, Germani, Aldo, Rutigliano, Monica, Stella, Alessandro, Bagnulo, Rosanna, Loconte, Daria, Galleggiante, Vanessa, Sanguedolce, Francesca, Cagiano, Simona, Bufo, Pantaleo, Trabucco, Senia, Maiorano, Eugenio, Ditonno, Pasquale, Battaglia, Michele, Resta, Nicoletta, Simone, Cristiano
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2113
container_issue 11
container_start_page 2102
container_title Autophagy
container_volume 11
creator Grossi, Valentina
Lucarelli, Giuseppe
Forte, Giovanna
Peserico, Alessia
Matrone, Antonio
Germani, Aldo
Rutigliano, Monica
Stella, Alessandro
Bagnulo, Rosanna
Loconte, Daria
Galleggiante, Vanessa
Sanguedolce, Francesca
Cagiano, Simona
Bufo, Pantaleo
Trabucco, Senia
Maiorano, Eugenio
Ditonno, Pasquale
Battaglia, Michele
Resta, Nicoletta
Simone, Cristiano
description Prostate cancer (PCa) is the second leading cause of cancer-related death in men; however, the molecular mechanisms leading to its development and progression are not yet fully elucidated. Of note, it has been recently shown that conditional stk11 knockout mice develop atypical hyperplasia and prostate intraepithelial neoplasia (PIN). We recently reported an inverse correlation between the activity of the STK11/AMPK pathway and the MAPK/p38 cascade in HIF1A-dependent malignancies. Furthermore, MAPK/p38 overactivation was detected in benign prostate hyperplasia, PIN and PCa in mice and humans. Here we report that STK11 expression is significantly decreased in PCa compared to normal tissues. Moreover, STK11 protein levels decreased throughout prostate carcinogenesis. To gain insight into the role of STK11-MAPK/p38 activity balance in PCa, we treated PCa cell lines and primary biopsies with a well-established MAPK14-MAPK11 inhibitor (SB202190), which has been extensively used in vitro and in vivo. Our results indicate that inhibition of MAPK/p38 significantly affects PCa cell survival in an STK11-dependent manner. Indeed, we found that pharmacologic inactivation of MAPK/p38 does not affect viability of STK11-proficient PCa cells due to the triggering of the AMPK-dependent autophagic pathway, while it induces apoptosis in STK11-deficient cells irrespective of androgen receptor (AR) status. Of note, AMPK inactivation or autophagy inhibition in STK11-proficient cells sensitize SB202190-treated PCa cells to apoptosis. On the other end, reconstitution of functional STK11 in STK11-deficient PCa cells abrogates apoptosis. Collectively, our data show that STK11 is a key factor involved in the early phases of prostate carcinogenesis, and suggest that it might be used as a predictive marker of therapeutic response to MAPK/p38 inhibitors in PCa patients.
doi_str_mv 10.1080/15548627.2015.1091910
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4824604</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1826639917</sourcerecordid><originalsourceid>FETCH-LOGICAL-c468t-1d2c799cb8686e20532c66f8d826651864f53fb39ef080249dd86a0fa8c02fb53</originalsourceid><addsrcrecordid>eNp9kctuUzEQhi0EoqXwCCAv2aT15dixN4iq4qYGgURZW449To1O7IPtFPIOPDQOSSPYsLI1880_lx-h55ScU6LIBRViUJLNzxmhooc01ZQ8QKe7-ExJLh4e_2x-gp7U-o0QLpVmj9EJk1zTQYhT9GuRa8U54C8315Ri-DkVqDXmhGPFNmGwZdxiuIPUcEx4Krk22wA7W1xMeQUJ6h_S9xz46FrF7RaKnWDTosNdbcqpAm4ZN1tW0MAfgC22KxtTbfjj5efri4mrp-hRsGOFZ4f3DH19--bm6v1s8endh6vLxcwNUrUZ9czNtXZLJZUERgRnTsqgvGJSCqrkEAQPS64h9EuxQXuvpCXBKkdYWAp-hl7tdafNcg3e9eWKHc1U4tqWrck2mn8zKd6aVb4zg2KDJEMXeHkQKPn7Bmoz61gdjKNNkDfV0N0kXGs676jYo66frhYIxzaUmJ2T5t5Js3PSHJzsdS_-nvFYdW9dB17vgZhCLmv7I5fRm2a3Yy6h2ORiNfz_PX4DzFKv8Q</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1826639917</pqid></control><display><type>article</type><title>Loss of STK11 expression is an early event in prostate carcinogenesis and predicts therapeutic response to targeted therapy against MAPK/p38</title><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Grossi, Valentina ; Lucarelli, Giuseppe ; Forte, Giovanna ; Peserico, Alessia ; Matrone, Antonio ; Germani, Aldo ; Rutigliano, Monica ; Stella, Alessandro ; Bagnulo, Rosanna ; Loconte, Daria ; Galleggiante, Vanessa ; Sanguedolce, Francesca ; Cagiano, Simona ; Bufo, Pantaleo ; Trabucco, Senia ; Maiorano, Eugenio ; Ditonno, Pasquale ; Battaglia, Michele ; Resta, Nicoletta ; Simone, Cristiano</creator><creatorcontrib>Grossi, Valentina ; Lucarelli, Giuseppe ; Forte, Giovanna ; Peserico, Alessia ; Matrone, Antonio ; Germani, Aldo ; Rutigliano, Monica ; Stella, Alessandro ; Bagnulo, Rosanna ; Loconte, Daria ; Galleggiante, Vanessa ; Sanguedolce, Francesca ; Cagiano, Simona ; Bufo, Pantaleo ; Trabucco, Senia ; Maiorano, Eugenio ; Ditonno, Pasquale ; Battaglia, Michele ; Resta, Nicoletta ; Simone, Cristiano</creatorcontrib><description>Prostate cancer (PCa) is the second leading cause of cancer-related death in men; however, the molecular mechanisms leading to its development and progression are not yet fully elucidated. Of note, it has been recently shown that conditional stk11 knockout mice develop atypical hyperplasia and prostate intraepithelial neoplasia (PIN). We recently reported an inverse correlation between the activity of the STK11/AMPK pathway and the MAPK/p38 cascade in HIF1A-dependent malignancies. Furthermore, MAPK/p38 overactivation was detected in benign prostate hyperplasia, PIN and PCa in mice and humans. Here we report that STK11 expression is significantly decreased in PCa compared to normal tissues. Moreover, STK11 protein levels decreased throughout prostate carcinogenesis. To gain insight into the role of STK11-MAPK/p38 activity balance in PCa, we treated PCa cell lines and primary biopsies with a well-established MAPK14-MAPK11 inhibitor (SB202190), which has been extensively used in vitro and in vivo. Our results indicate that inhibition of MAPK/p38 significantly affects PCa cell survival in an STK11-dependent manner. Indeed, we found that pharmacologic inactivation of MAPK/p38 does not affect viability of STK11-proficient PCa cells due to the triggering of the AMPK-dependent autophagic pathway, while it induces apoptosis in STK11-deficient cells irrespective of androgen receptor (AR) status. Of note, AMPK inactivation or autophagy inhibition in STK11-proficient cells sensitize SB202190-treated PCa cells to apoptosis. On the other end, reconstitution of functional STK11 in STK11-deficient PCa cells abrogates apoptosis. Collectively, our data show that STK11 is a key factor involved in the early phases of prostate carcinogenesis, and suggest that it might be used as a predictive marker of therapeutic response to MAPK/p38 inhibitors in PCa patients.</description><identifier>ISSN: 1554-8627</identifier><identifier>EISSN: 1554-8635</identifier><identifier>DOI: 10.1080/15548627.2015.1091910</identifier><identifier>PMID: 26391455</identifier><language>eng</language><publisher>United States: Taylor &amp; Francis</publisher><subject>AMPK ; apoptosis ; autophagy ; drug resistance ; MAPK/p38 ; prostate cancer ; STK11 ; Translational Research Paper</subject><ispartof>Autophagy, 2015-11, Vol.11 (11), p.2102-2113</ispartof><rights>2015 Taylor &amp; Francis Group, LLC 2015</rights><rights>2015 Taylor &amp; Francis Group, LLC 2015 Taylor &amp; Francis</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c468t-1d2c799cb8686e20532c66f8d826651864f53fb39ef080249dd86a0fa8c02fb53</citedby><cites>FETCH-LOGICAL-c468t-1d2c799cb8686e20532c66f8d826651864f53fb39ef080249dd86a0fa8c02fb53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4824604/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4824604/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26391455$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Grossi, Valentina</creatorcontrib><creatorcontrib>Lucarelli, Giuseppe</creatorcontrib><creatorcontrib>Forte, Giovanna</creatorcontrib><creatorcontrib>Peserico, Alessia</creatorcontrib><creatorcontrib>Matrone, Antonio</creatorcontrib><creatorcontrib>Germani, Aldo</creatorcontrib><creatorcontrib>Rutigliano, Monica</creatorcontrib><creatorcontrib>Stella, Alessandro</creatorcontrib><creatorcontrib>Bagnulo, Rosanna</creatorcontrib><creatorcontrib>Loconte, Daria</creatorcontrib><creatorcontrib>Galleggiante, Vanessa</creatorcontrib><creatorcontrib>Sanguedolce, Francesca</creatorcontrib><creatorcontrib>Cagiano, Simona</creatorcontrib><creatorcontrib>Bufo, Pantaleo</creatorcontrib><creatorcontrib>Trabucco, Senia</creatorcontrib><creatorcontrib>Maiorano, Eugenio</creatorcontrib><creatorcontrib>Ditonno, Pasquale</creatorcontrib><creatorcontrib>Battaglia, Michele</creatorcontrib><creatorcontrib>Resta, Nicoletta</creatorcontrib><creatorcontrib>Simone, Cristiano</creatorcontrib><title>Loss of STK11 expression is an early event in prostate carcinogenesis and predicts therapeutic response to targeted therapy against MAPK/p38</title><title>Autophagy</title><addtitle>Autophagy</addtitle><description>Prostate cancer (PCa) is the second leading cause of cancer-related death in men; however, the molecular mechanisms leading to its development and progression are not yet fully elucidated. Of note, it has been recently shown that conditional stk11 knockout mice develop atypical hyperplasia and prostate intraepithelial neoplasia (PIN). We recently reported an inverse correlation between the activity of the STK11/AMPK pathway and the MAPK/p38 cascade in HIF1A-dependent malignancies. Furthermore, MAPK/p38 overactivation was detected in benign prostate hyperplasia, PIN and PCa in mice and humans. Here we report that STK11 expression is significantly decreased in PCa compared to normal tissues. Moreover, STK11 protein levels decreased throughout prostate carcinogenesis. To gain insight into the role of STK11-MAPK/p38 activity balance in PCa, we treated PCa cell lines and primary biopsies with a well-established MAPK14-MAPK11 inhibitor (SB202190), which has been extensively used in vitro and in vivo. Our results indicate that inhibition of MAPK/p38 significantly affects PCa cell survival in an STK11-dependent manner. Indeed, we found that pharmacologic inactivation of MAPK/p38 does not affect viability of STK11-proficient PCa cells due to the triggering of the AMPK-dependent autophagic pathway, while it induces apoptosis in STK11-deficient cells irrespective of androgen receptor (AR) status. Of note, AMPK inactivation or autophagy inhibition in STK11-proficient cells sensitize SB202190-treated PCa cells to apoptosis. On the other end, reconstitution of functional STK11 in STK11-deficient PCa cells abrogates apoptosis. Collectively, our data show that STK11 is a key factor involved in the early phases of prostate carcinogenesis, and suggest that it might be used as a predictive marker of therapeutic response to MAPK/p38 inhibitors in PCa patients.</description><subject>AMPK</subject><subject>apoptosis</subject><subject>autophagy</subject><subject>drug resistance</subject><subject>MAPK/p38</subject><subject>prostate cancer</subject><subject>STK11</subject><subject>Translational Research Paper</subject><issn>1554-8627</issn><issn>1554-8635</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNp9kctuUzEQhi0EoqXwCCAv2aT15dixN4iq4qYGgURZW449To1O7IPtFPIOPDQOSSPYsLI1880_lx-h55ScU6LIBRViUJLNzxmhooc01ZQ8QKe7-ExJLh4e_2x-gp7U-o0QLpVmj9EJk1zTQYhT9GuRa8U54C8315Ri-DkVqDXmhGPFNmGwZdxiuIPUcEx4Krk22wA7W1xMeQUJ6h_S9xz46FrF7RaKnWDTosNdbcqpAm4ZN1tW0MAfgC22KxtTbfjj5efri4mrp-hRsGOFZ4f3DH19--bm6v1s8endh6vLxcwNUrUZ9czNtXZLJZUERgRnTsqgvGJSCqrkEAQPS64h9EuxQXuvpCXBKkdYWAp-hl7tdafNcg3e9eWKHc1U4tqWrck2mn8zKd6aVb4zg2KDJEMXeHkQKPn7Bmoz61gdjKNNkDfV0N0kXGs676jYo66frhYIxzaUmJ2T5t5Js3PSHJzsdS_-nvFYdW9dB17vgZhCLmv7I5fRm2a3Yy6h2ORiNfz_PX4DzFKv8Q</recordid><startdate>20151102</startdate><enddate>20151102</enddate><creator>Grossi, Valentina</creator><creator>Lucarelli, Giuseppe</creator><creator>Forte, Giovanna</creator><creator>Peserico, Alessia</creator><creator>Matrone, Antonio</creator><creator>Germani, Aldo</creator><creator>Rutigliano, Monica</creator><creator>Stella, Alessandro</creator><creator>Bagnulo, Rosanna</creator><creator>Loconte, Daria</creator><creator>Galleggiante, Vanessa</creator><creator>Sanguedolce, Francesca</creator><creator>Cagiano, Simona</creator><creator>Bufo, Pantaleo</creator><creator>Trabucco, Senia</creator><creator>Maiorano, Eugenio</creator><creator>Ditonno, Pasquale</creator><creator>Battaglia, Michele</creator><creator>Resta, Nicoletta</creator><creator>Simone, Cristiano</creator><general>Taylor &amp; Francis</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20151102</creationdate><title>Loss of STK11 expression is an early event in prostate carcinogenesis and predicts therapeutic response to targeted therapy against MAPK/p38</title><author>Grossi, Valentina ; Lucarelli, Giuseppe ; Forte, Giovanna ; Peserico, Alessia ; Matrone, Antonio ; Germani, Aldo ; Rutigliano, Monica ; Stella, Alessandro ; Bagnulo, Rosanna ; Loconte, Daria ; Galleggiante, Vanessa ; Sanguedolce, Francesca ; Cagiano, Simona ; Bufo, Pantaleo ; Trabucco, Senia ; Maiorano, Eugenio ; Ditonno, Pasquale ; Battaglia, Michele ; Resta, Nicoletta ; Simone, Cristiano</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c468t-1d2c799cb8686e20532c66f8d826651864f53fb39ef080249dd86a0fa8c02fb53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>AMPK</topic><topic>apoptosis</topic><topic>autophagy</topic><topic>drug resistance</topic><topic>MAPK/p38</topic><topic>prostate cancer</topic><topic>STK11</topic><topic>Translational Research Paper</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Grossi, Valentina</creatorcontrib><creatorcontrib>Lucarelli, Giuseppe</creatorcontrib><creatorcontrib>Forte, Giovanna</creatorcontrib><creatorcontrib>Peserico, Alessia</creatorcontrib><creatorcontrib>Matrone, Antonio</creatorcontrib><creatorcontrib>Germani, Aldo</creatorcontrib><creatorcontrib>Rutigliano, Monica</creatorcontrib><creatorcontrib>Stella, Alessandro</creatorcontrib><creatorcontrib>Bagnulo, Rosanna</creatorcontrib><creatorcontrib>Loconte, Daria</creatorcontrib><creatorcontrib>Galleggiante, Vanessa</creatorcontrib><creatorcontrib>Sanguedolce, Francesca</creatorcontrib><creatorcontrib>Cagiano, Simona</creatorcontrib><creatorcontrib>Bufo, Pantaleo</creatorcontrib><creatorcontrib>Trabucco, Senia</creatorcontrib><creatorcontrib>Maiorano, Eugenio</creatorcontrib><creatorcontrib>Ditonno, Pasquale</creatorcontrib><creatorcontrib>Battaglia, Michele</creatorcontrib><creatorcontrib>Resta, Nicoletta</creatorcontrib><creatorcontrib>Simone, Cristiano</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Autophagy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Grossi, Valentina</au><au>Lucarelli, Giuseppe</au><au>Forte, Giovanna</au><au>Peserico, Alessia</au><au>Matrone, Antonio</au><au>Germani, Aldo</au><au>Rutigliano, Monica</au><au>Stella, Alessandro</au><au>Bagnulo, Rosanna</au><au>Loconte, Daria</au><au>Galleggiante, Vanessa</au><au>Sanguedolce, Francesca</au><au>Cagiano, Simona</au><au>Bufo, Pantaleo</au><au>Trabucco, Senia</au><au>Maiorano, Eugenio</au><au>Ditonno, Pasquale</au><au>Battaglia, Michele</au><au>Resta, Nicoletta</au><au>Simone, Cristiano</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Loss of STK11 expression is an early event in prostate carcinogenesis and predicts therapeutic response to targeted therapy against MAPK/p38</atitle><jtitle>Autophagy</jtitle><addtitle>Autophagy</addtitle><date>2015-11-02</date><risdate>2015</risdate><volume>11</volume><issue>11</issue><spage>2102</spage><epage>2113</epage><pages>2102-2113</pages><issn>1554-8627</issn><eissn>1554-8635</eissn><abstract>Prostate cancer (PCa) is the second leading cause of cancer-related death in men; however, the molecular mechanisms leading to its development and progression are not yet fully elucidated. Of note, it has been recently shown that conditional stk11 knockout mice develop atypical hyperplasia and prostate intraepithelial neoplasia (PIN). We recently reported an inverse correlation between the activity of the STK11/AMPK pathway and the MAPK/p38 cascade in HIF1A-dependent malignancies. Furthermore, MAPK/p38 overactivation was detected in benign prostate hyperplasia, PIN and PCa in mice and humans. Here we report that STK11 expression is significantly decreased in PCa compared to normal tissues. Moreover, STK11 protein levels decreased throughout prostate carcinogenesis. To gain insight into the role of STK11-MAPK/p38 activity balance in PCa, we treated PCa cell lines and primary biopsies with a well-established MAPK14-MAPK11 inhibitor (SB202190), which has been extensively used in vitro and in vivo. Our results indicate that inhibition of MAPK/p38 significantly affects PCa cell survival in an STK11-dependent manner. Indeed, we found that pharmacologic inactivation of MAPK/p38 does not affect viability of STK11-proficient PCa cells due to the triggering of the AMPK-dependent autophagic pathway, while it induces apoptosis in STK11-deficient cells irrespective of androgen receptor (AR) status. Of note, AMPK inactivation or autophagy inhibition in STK11-proficient cells sensitize SB202190-treated PCa cells to apoptosis. On the other end, reconstitution of functional STK11 in STK11-deficient PCa cells abrogates apoptosis. Collectively, our data show that STK11 is a key factor involved in the early phases of prostate carcinogenesis, and suggest that it might be used as a predictive marker of therapeutic response to MAPK/p38 inhibitors in PCa patients.</abstract><cop>United States</cop><pub>Taylor &amp; Francis</pub><pmid>26391455</pmid><doi>10.1080/15548627.2015.1091910</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1554-8627
ispartof Autophagy, 2015-11, Vol.11 (11), p.2102-2113
issn 1554-8627
1554-8635
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4824604
source EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects AMPK
apoptosis
autophagy
drug resistance
MAPK/p38
prostate cancer
STK11
Translational Research Paper
title Loss of STK11 expression is an early event in prostate carcinogenesis and predicts therapeutic response to targeted therapy against MAPK/p38
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T01%3A53%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Loss%20of%20STK11%20expression%20is%20an%20early%20event%20in%20prostate%20carcinogenesis%20and%20predicts%20therapeutic%20response%20to%20targeted%20therapy%20against%20MAPK/p38&rft.jtitle=Autophagy&rft.au=Grossi,%20Valentina&rft.date=2015-11-02&rft.volume=11&rft.issue=11&rft.spage=2102&rft.epage=2113&rft.pages=2102-2113&rft.issn=1554-8627&rft.eissn=1554-8635&rft_id=info:doi/10.1080/15548627.2015.1091910&rft_dat=%3Cproquest_pubme%3E1826639917%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1826639917&rft_id=info:pmid/26391455&rfr_iscdi=true